SciSparc Total Long Term Liabilities 2017-2024 | SPRC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

SciSparc total long term liabilities from 2017 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

SciSparc total long term liabilities from 2017 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$70.5B
Zoetis (ZTS)	$69.4B
Takeda Pharmaceutical (TAK)	$49.4B
Daiichi Sankyo, - (DSNKY)	$48.3B
BeOne Medicines - (ONC)	$34.4B
Sandoz Group AG (SDZNY)	$27.6B
Summit Therapeutics (SMMT)	$19.5B
Merck (MKKGY)	$17B
Shionogi (SGIOY)	$14.9B
United Therapeutics (UTHR)	$14.1B
Neurocrine Biosciences (NBIX)	$13.4B
IPSEN (IPSEY)	$11.4B
Orion OYJ (ORINY)	$11.3B
Eisai (ESAIY)	$9.3B
Madrigal Pharmaceuticals (MDGL)	$9.2B
Corcept Therapeutics (CORT)	$7.4B
Grifols, S.A (GRFS)	$7B
Stevanato Group S.p.A (STVN)	$6.9B
Ionis Pharmaceuticals (IONS)	$6.8B
Ono Pharmaceutical (OPHLF)	$5.7B
Hikma Pharmaceuticals Plc (HKMPF)	$5.4B
Soleno Therapeutics (SLNO)	$3.6B
Procaps Group, S.A (PROCF)	$3.2B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$3B
Crinetics Pharmaceuticals (CRNX)	$2.9B
NewAmsterdam Pharma (NAMS)	$2.8B
Catalyst Pharmaceuticals (CPRX)	$2.6B
Hypermarcas (HYPMY)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.3B
Ocular Therapeutix (OCUL)	$2.1B